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scheduled for an office visit within the next 3 weeks for an anti-VEGF injection or 
monitoring. Additionally, a survey was administered to 75 patients with NVAMD 
who were aged ≥ 50 years and had received ≥ 1 anti-VEGF injection in the past 
6 months. Furthermore, telephone interviews were conducted with 13 caregivers 
of patients with NVAMD. Results: 56 physicians provided data for 221 patients 
with NVAMD. Management of patients with NVAMD comprised 20% of the health 
care staff’s working week, with an average of 24 staff members involved. An aver-
age patient visit for management of NVAMD was 90 minutes (range: 13 minutes 
to > 4 hours). Patients reported an average time commitment per visit of almost 
12 hours, including preappointment preparation (16 minutes), travel (66 minutes), 
waiting time (37 minutes), treatment time (43 minutes), and recovery (9 hours). 
Caregivers reported taking time away from work (> 20%) and personal activities (> 
25%) to accompany patients to appointments. ConClusions: NVAMD manage-
ment imposes a substantial time burden on physicians and other staff members, 
as well as patients and caregivers. There may be a need for additional support and/
or reimbursement for services required by patients and caregivers, as well as those 
provided by physicians.
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objeCtives: To gain an understanding of the use of self-administered topical 
therapies for actinic keratosis exploring patients’ persistence and adherence 
behaviour. Methods: The study was conducted as an online longitudinal ques-
tionnaire-based survey in the UK, France and Germany between October 2012 
and May 2013, among AK patients diagnosed and recruited by a physician +/- one 
week from any topical therapy initiation. The study design consisted of a base-
line questionnaire followed by up to 6 follow-up questionnaires, completed at 
fortnightly intervals to cover a full treatment course. Persistence was calculated 
as persistence % = (Actual days of use/Advised days of use) x 100 and Adherence 
as Adherence % = (Actual times of use/Advised times of use) x 100, both were 
calculated using thresholds of 100% and 80%. Logistic regression modelling (mul-
tivariate analysis) was also performed to investigate causes of non-adherence/
persistence among the patients. Results: Overall, 224 patients completed the 
baseline questionnaire. Over 50% of the sample were prescribed diclofenac sodium 
at baseline, the remaining patients had been prescribed any of imiquimode 5 % 
or 3,75%, fluorouracil, or fluorouracil + salicylicacid. Over the course of the study 
approximately 2/3 of the patients remained on the same therapy from baseline to 
the end of the study and 1/3 ceased therapy or switched at least once. The majority 
of cases occurred on instruction from a health care professional (HCP). Of those 
who ceased or switched therapy, 79-94% of patients being non-persistent to their 
prescribed treatment duration, however, over 90% of patients were reported to 
be adherent to application. Controlled for treatment, gender and quality of life, 
patients aged > 60 years were significantly more adherent compared to patients 
aged < 60 years. ConClusions: This study reports that 1/3 of topical AK patients 
switch or prematurely stop treatment suggesting that patients experience issues 
preventing completion of treatment course.
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objeCtives: Adherence to medications is a significant problem in glaucoma 
patients. Costs of medications have frequently been cited as barriers to adherence. 
This study aims to identify the extent of physician-patient communication concern-
ing medication cost during glaucoma medical visits. The study also aims to examine 
ophthalmologist and patient characteristics that influence whether the ophthal-
mologist discusses medication costs with the patient during glaucoma medical 
visits. Methods: English-speaking adults with glaucoma and their ophthalmolo-
gists at six geographically diverse ophthalmology practices were recruited for the 
study. All visits were videotape recorded and transcribed verbatim. Patients were 
interviewed following their office visit. A research assistant reviewed the patient’s 
medical records noting comorbidities, glaucoma medication use, and glaucoma 
severity. Ophthalmologists completed a demographic survey. Transcripts were 
coded to identify whether the ophthalmologist discussed medication cost with 
the patient during the office visit. Bivariate analyses were performed to examine 
whether ophthalmologist and patient characteristics were associated with discus-
sion of medication cost. Results: Fifteen ophthalmologists and 279 of their glau-
coma patients participated in the study. Ophthalmologists discussed medication 
costs during only 67 (24%) of glaucoma medical visits. Ophthalmologists with more 
years of experience practicing were significantly more likely to discuss medica-
tion cost (p< 0.03). Also, ophthalmologists were significantly more likely to discuss 
medication cost with patients who had higher levels of formal education, were new 
to using glaucoma medications, and were taking more glaucoma medications (p< 
0.05). ConClusions: Ophthalmologists do not routinely discuss medication cost 
during glaucoma patient office visits. Future research is needed to investigate the 
impact of physician-patient communication concerning medication cost on adher-
ence in the glaucoma patient population.
the cost assumptions. When failed EUS were assumed to be completed as EUA, 
the mean cost of EUS increased to $586 (95% CI $438, $735), but remained signifi-
cantly less than EUA. ConClusions: Hospitals pressured to rationalize care cre-
ate opportunities for early HTA. Cross-over designs are promising for assessments 
of costs and effectiveness of emerging technologies because patients serve as their 
own control. This study demonstrated significant savings when ophthalmologic 
exams were carried out in a hospital outpatient clinic, albeit with slightly fewer 
procedures completed.
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objeCtives: Persistent attachment between the vitreous and the macula causes 
vitreomacular traction (VMT) and subsequent formation of a macular hole (MH) 
leading to symptomatic loss of visual function. This analysis estimated long-term 
benefits and costs associated with the resolution of traction following treatment 
with ocriplasmin versus standard-of-care (observation, followed by vitrectomy if 
needed), in the French health care system, from a collective perspective. Methods: 
The model included (1) a short-term decision-tree, simulating 6-month anatomi-
cal and visual outcomes observed in the two Phase III MIVI-TRUST ocriplasmin 
randomized controlled trials (RCTs), and (2) a long-term Markov state-transition 
model, tracking patients over a lifetime-period. Both models were linked through 
common health states based on VMT resolution or MH closure, number of vitrec-
tomies and visual acuity status. Effectiveness and safety outcomes were based on 
the MIVI-TRUST RCTs. Patient populations included (1) total licensed VMT popula-
tion, independent of the presence/absence of a MH, and two subgroups according 
to pre-specified analyses (2) VMT with epiretinal membrane (ERM), and (3) VMT 
without ERM. Benefit was measured in quality-adjusted life years (QALYs), based 
on (1) time spent in health states defined by the visual acuity of the best and worse 
seeing eye, (2) disutility impact associated with surgical interventions (vitrectomy 
and cataract), adverse events and metamorphopsia. Resources used with ocriplas-
min and standard-of-care were based on expert opinions. Unit costs were mainly 
drawn from the French national hospital database. Results: Over a life-time, ocri-
plasmin versus standard-of-care generated incremental benefits in terms of QALYs 
and overall treatment costs in group (1) 0.071; € 2,107 (2) 0.034; € 2,689, and (3) 0.093; 
€ 1,757. Lifetime per-patient cost/QALY was € 29,767; € 78,393, and € 18,917, respec-
tively. ConClusions: Applying commonly accepted cost-effectiveness thresholds 
(€ 35,000-€ 50,000/QALY), this first French cost-utility analysis shows that ocriplasmin 
represents a cost-effective strategy in total licensed VMT population, and particu-
larly in patients without ERM.
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objeCtives: To evaluate the cost-effectiveness of intravitreal aflibercept compared 
with ranibizumab and bevacizumab for wet age-related macular degeneration 
(AMD) patients. Methods: A Markov model was applied in cost-utility analysis to 
evaluate the incremental cost-effectiveness ratio (ICER) between aflibercept, ranibi-
zumab, and bevacizumab from societal perspective over 12 years. Patients switched 
to as-needed based dosing after one year on the FDA approved regimens. Yearly 
transitional probabilities were obtained and extrapolated from two-year randomized 
control trials. Direct medical costs, resource utilization and utility scores were esti-
mated and calculated using the Medicare National Physician Fee Schedule and other 
published studies. Costs were adjusted and reported in 2013 US dollar. Base case 
was a 78 year-old patient with vision acuity at 60-letter level. The cost-effectiveness 
threshold was $ 51,749, as three-fold GDP per capita in 2013. One-way sensitivity 
analyses were performed to test for the robustness of the model. Results: The 
cost-effectiveness ratio (CER) for aflibercept, ranibizumab, and bevacizumab were 
$31,404, $34,888, 43,096, respectively. The ICER for aflibercept was dominant com-
pared to both ranibizumab and bevacizumab. When caregiver costs were excluded, 
bevacizumab became the cost-effective treatment (dominated by ranibizumab; the 
ICER for aflibercept was $73,625). The number of as-needed doses, instruments 
used for obtaining utility, initial level of vision acuity level and variation in drug 
costs demonstrated small impact on relative cost-effectiveness. ConClusions: 
Aflibercept was the cost-effective treatment for AMD patients compared to ranibi-
zumab and bevacizumab from societal perspective.
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objeCtives: Neovascular age-related macular degeneration (NVAMD) is a costly, 
debilitating, and progressive disease that profoundly impacts patients’ visual 
acuity. NVAMD is the leading cause of blindness in the developed world. This 
time-and-motion study investigated the physician, patient, and caregiver time 
burden associated with the management of patients with NVAMD in the United 
States. Methods: Quantitative research was conducted in June 2011 and August 
2012. A survey was conducted with 57 retina specialists who administered ≥ 50 
vascular endothelial growth factor (VEGF)-inhibitor injections per month; 56 of 
these physicians completed records (patient history and diaries) for ≤ 5 patients 
